The EU AI Act is poised to reshape the landscape of AI in pharmaceutical and healthcare innovation. While many perceive it as a regulatory hurdle, Boehringer Ingelheim views it as a unique opportunity to solidify its position as a leader in responsible and trustworthy AI. During this session Micheal Scrhopp, Head of Digital Innovation for Regulatory Affairs will delve into how Boehringer Ingelheim is strategically leveraging the EU AI Act to not only ensure compliance but also to unlock significant competitive advantages. Micheal will explore the Act’s unique selling proposition for European pharma, how it can be transformed into a valuable asset for clients and regulators, alongside providing actionable tips for organizations to embrace this regulatory shift as a catalyst for innovation.

Key Talking Points:

• Strategy Implementation: Explore Boehringer Ingelheim’s proactive approach to navigating the Act and transforming compliance into a strategic advantage
• The European Outlook: Identify the USP the AI act brings to European pharma
• Being Prepared: Gain practical insights and actionable tips for preparing your organization for the EU AI Act